Wainer Andrea F.'s most recent trade in Abbott Laboratories was a trade of 7,313 Common shares without par value done at an average price of $135.9 . Disclosure was reported to the exchange on Feb. 28, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Abbott Laboratories | Andrea F. Wainer | RETIRED EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.87 per share. | 28 Feb 2025 | 7,313 | 75,330 (0%) | 0% | 135.9 | 993,617 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | RETIRED EVP | Sale of securities on an exchange or to another person at price $ 138.17 per share. | 28 Feb 2025 | 949 | 74,381 (0%) | 0% | 138.2 | 131,123 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 45,730 | 45,730 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 12,278 | 82,643 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.05 per share. | 29 Feb 2024 | 8,339 | 70,365 (0%) | 0% | 120.1 | 1,001,097 | Common shares without par value |
Abbott Laboratories | F. Andrea Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 12,500 | 34,449 | - | - | Option (right to buy) | |
Abbott Laboratories | F. Wainer Andrea | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.94 per share. | 23 Feb 2024 | 12,500 | 91,204 (0%) | 0% | 59.9 | 749,250 | Common shares without par value |
Abbott Laboratories | F. Wainer Andrea | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 23 Feb 2024 | 12,500 | 78,704 (0%) | 0% | 120 | 1,500,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 51,397 | 51,397 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea Wainer F. | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 13,677 | 78,704 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Wainer F. Andrea | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 112.50 per share. | 29 Jan 2024 | 25,000 | 65,027 (0%) | 0% | 112.5 | 2,812,500 | Common shares without par value |
Abbott Laboratories | Wainer Andrea F. | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.40 per share. | 29 Jan 2024 | 25,000 | 90,027 (0%) | 0% | 44.4 | 1,110,000 | Common shares without par value |
Abbott Laboratories | Wainer Andrea F. | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 25,000 | 13,271 | - | - | Option (right to buy) | |
Abbott Laboratories | Wainer Andrea F. | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 17,500 | 46,949 | - | - | Option (right to buy) | |
Abbott Laboratories | Wainer F. Andrea | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 112.50 per share. | 29 Jan 2024 | 17,500 | 65,027 (0%) | 0% | 112.5 | 1,968,750 | Common shares without par value |
Abbott Laboratories | F. Wainer Andrea | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.94 per share. | 29 Jan 2024 | 17,500 | 82,527 (0%) | 0% | 59.9 | 1,048,950 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 14 Dec 2023 | 15,000 | 65,027 (0%) | 0% | 108 | 1,620,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.40 per share. | 14 Dec 2023 | 15,000 | 80,027 (0%) | 0% | 44.4 | 666,000 | Common shares without par value |
Abbott Laboratories | F. Andrea Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 15,000 | 38,271 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Aug 2023 | 5,112 | 65,315 (0%) | 0% | 105 | 536,760 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 08 Aug 2023 | 5,000 | 75,427 (0%) | 0% | 38.4 | 192,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 5,000 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Aug 2023 | 4,741 | 70,686 (0%) | 0% | 105 | 497,805 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 105.43 per share. | 08 Aug 2023 | 272 | 65,043 (0%) | 0% | 105.4 | 28,677 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 105.43 per share. | 08 Aug 2023 | 244 | 70,442 (0%) | 0% | 105.4 | 25,725 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 107.44 per share. | 08 Aug 2023 | 16 | 65,027 (0%) | 0% | 107.4 | 1,719 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 107.40 per share. | 08 Aug 2023 | 15 | 70,427 (0%) | 0% | 107.4 | 1,611 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 02 May 2023 | 8,226 | 78,653 (0%) | 0% | 47 | 386,622 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2023 | 8,226 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 110.56 per share. | 02 May 2023 | 8,226 | 70,427 (0%) | 0% | 110.6 | 909,472 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 7,531 | 71,106 (0%) | 0% | 99.8 | 751,368 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 100.70 per share. | 28 Feb 2023 | 679 | 70,427 (0%) | 0% | 100.7 | 68,375 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 71,907 | 71,907 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 18,233 | 78,637 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.51 per share. | 03 Jun 2022 | 1,768 | 60,404 (0%) | 0% | 117.5 | 207,758 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 6,126 | 62,628 (0%) | 0% | 122.4 | 749,884 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.13 per share. | 28 Feb 2022 | 456 | 62,172 (0%) | 0% | 118.1 | 53,866 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 88,418 | 88,418 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 18,972 | 68,754 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 23 Dec 2021 | 13,000 | 49,782 (0%) | 0% | 140 | 1,820,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 23 Dec 2021 | 10,000 | 62,782 (0%) | 0% | 38.4 | 384,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 10,000 | 5,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 23 Dec 2021 | 3,000 | 52,782 (0%) | 0% | 47 | 141,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 3,000 | 8,226 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 3,000 | 11,226 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 23 Dec 2021 | 3,000 | 52,782 (0%) | 0% | 47 | 141,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 142.50 per share. | 23 Dec 2021 | 3,000 | 49,782 (0%) | 0% | 142.5 | 427,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 137.54 per share. | 17 Dec 2021 | 7,500 | 49,782 (0%) | 0% | 137.5 | 1,031,550 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 7,500 | 14,226 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 17 Dec 2021 | 7,500 | 57,282 (0%) | 0% | 47 | 352,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 13 Dec 2021 | 14,500 | 49,782 (0%) | 0% | 135 | 1,957,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 13 Dec 2021 | 7,500 | 64,282 (0%) | 0% | 38.4 | 288,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 7,500 | 15,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 7,000 | 21,726 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 13 Dec 2021 | 7,000 | 56,782 (0%) | 0% | 47 | 329,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 132.50 per share. | 06 Dec 2021 | 4,500 | 49,782 (0%) | 0% | 132.5 | 596,250 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 06 Dec 2021 | 4,500 | 54,282 (0%) | 0% | 47 | 211,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2021 | 4,500 | 28,726 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 130.01 per share. | 15 Nov 2021 | 12,500 | 49,782 (0%) | 0% | 130.0 | 1,625,111 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 7,500 | 22,500 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 15 Nov 2021 | 7,500 | 62,282 (0%) | 0% | 38.4 | 288,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 15 Nov 2021 | 5,000 | 54,782 (0%) | 0% | 47 | 235,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 5,000 | 33,226 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 127.50 per share. | 02 Sep 2021 | 9,500 | 49,782 (0%) | 0% | 127.5 | 1,211,250 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 02 Sep 2021 | 5,000 | 59,282 (0%) | 0% | 38.4 | 192,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 5,000 | 30,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 4,500 | 38,226 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 02 Sep 2021 | 4,500 | 54,282 (0%) | 0% | 47 | 211,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 17 Aug 2021 | 14,500 | 49,782 (0%) | 0% | 125 | 1,812,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 17 Aug 2021 | 10,000 | 64,282 (0%) | 0% | 38.4 | 384,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 10,000 | 35,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 4,500 | 42,726 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 17 Aug 2021 | 4,500 | 54,282 (0%) | 0% | 47 | 211,500 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.90 per share. | 03 Jun 2021 | 1,768 | 49,782 (0%) | 0% | 106.9 | 188,999 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 121.79 per share. | 03 Mar 2021 | 6,200 | 51,550 (0%) | 0% | 121.8 | 755,098 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 5,000 | 58,337 (0%) | 0% | 121.6 | 607,900 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.61 per share. | 26 Feb 2021 | 587 | 57,750 (0%) | 0% | 120.6 | 70,798 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 98,708 | 98,708 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 19,257 | 63,337 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrea F. Wainer | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2020 | 30,000 | 45,000 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrea F. Wainer | Executive Vice President | Sale of securities on an exchange or to another person at price $ 107.01 per share. | 30 Sep 2020 | 30,000 | 44,080 (0%) | 0% | 107.0 | 3,210,360 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 30 Sep 2020 | 30,000 | 74,080 (0%) | 0% | 38.4 | 1,152,000 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | Executive Vice President | Sale of securities on an exchange or to another person at price $ 102.47 per share. | 23 Sep 2020 | 3,650 | 44,080 (0%) | 0% | 102.5 | 374,031 | Common shares without par value |
Abbott Laboratories | Andrea F. Wainer | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.62 per share. | 03 Jun 2020 | 1,768 | 47,730 (0%) | 0% | 92.6 | 163,752 | Common shares without par value |